Any use outside of a supervised clinical trial setting would be inappropriate and potentially unsafe
Individual results vary, and the drug is still under investigation, but these outcomes are considered groundbreaking in obesity medicine
It is a fair question to ask, especially when you see these medicines talked about everywhere
GLP-1 (glucagon-like peptide-1) receptor agonists have emerged as powerful tools in managing type 2 diabetes and obesity, offering significant benefits for weight reduction and metabolic health
see also Gawryluk JW, Wang J-F, Andreazza AC, Shao L, Young LT: Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders
however, clinical success is a subjective assessment and dependent on individual treatment targets for each participant